These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37684177)

  • 1. Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
    Rocco B; Sighinolfi MC
    Eur Urol; 2024 Feb; 85(2):e40. PubMed ID: 37684177
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
    Hamdy FC; Donovan JL
    Eur Urol; 2024 Feb; 85(2):e41-e42. PubMed ID: 37659961
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
    Hamdy FC; Donovan JL
    Eur Urol; 2024 Feb; 85(2):e54-e55. PubMed ID: 37949699
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Freddie C. Hamdy, Jennie L. Donovan, J. Athene Lane, et al. Fifteen-year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
    Campodonico F
    Eur Urol Oncol; 2024 Feb; 7(1):171. PubMed ID: 37474401
    [No Abstract]   [Full Text] [Related]  

  • 5. ProtecT trial: What's new after 15 years of follow-up: Re: Hamdy FC and colleagues; N Engl J Med. 2023 Apr 27.
    Terlizzi M; Bossi A
    Urologia; 2024 Feb; 91(1):3-4. PubMed ID: 38477298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. Hamdy et al. NEJM October 2016.
    Peters M; van der Voort van Zyp JRN; Verkooijen HM
    World J Urol; 2017 Sep; 35(9):1465. PubMed ID: 28210766
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above: A. Vickers, E. A. Vertosick, D. D. Sjoberg, M. J. Roobol, F. Hamdy, D. Neal, A. Bjartell, J. Hugosson, J. L. Donovan, A. Villers, S. Zappala and H. Lilja J Urol 2017;197:607-613.
    Shah N; Ioffe V
    J Urol; 2017 Aug; 198(2):445-446. PubMed ID: 28457843
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Chang D; Appu S; Siva S
    Eur Urol; 2023 Oct; 84(4):436-437. PubMed ID: 37268486
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Cooperberg MR
    Eur Urol; 2023 Oct; 84(4):435-436. PubMed ID: 37208238
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    Sharma AD; Lopez JF; Leiblich A; Leslie TA; Lamb AD
    Eur Urol; 2023 Aug; 84(2):245-246. PubMed ID: 37117110
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978.
    Eggener S
    Urol Oncol; 2014 May; 32(4):513-4. PubMed ID: 24767688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study.
    Olumi AF
    Urol Oncol; 2014 Feb; 32(2):211. PubMed ID: 24445293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
    Morote J
    Eur Urol Oncol; 2023 Apr; 6(2):234. PubMed ID: 36894492
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
    Lenfant L; Mozer P; Seisen T
    Eur Urol Oncol; 2023 Apr; 6(2):235. PubMed ID: 36707321
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142.
    Di Lorenzo G; Buonerba C
    Eur Urol; 2022 Jul; 82(1):e17. PubMed ID: 35393160
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Mahal BA; D'Amico AV; Nguyen PL
    Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Shore ND; Dearnaley D; Tombal B
    Eur Urol; 2020 Nov; 78(5):e196-e197. PubMed ID: 32838997
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003; 349: 215-224 and N Engl J Med 2003; 349: 335-342.
    Platz EA; De Marzo AM; Giovannucci E
    Cancer Causes Control; 2004 Feb; 15(1):91-4. PubMed ID: 14970739
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.
    Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
    Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
    Rizzo A; Mollica V; Massari F
    Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.